Arbutus Biopharma Corp Goodwill, Impairment Loss
Arbutus Biopharma Corp (ABUS) reported Goodwill, Impairment Loss of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GoodwillImpairmentLoss · last filed 2021-03-04
- Arbutus Biopharma Corp goodwill, impairment loss for the quarter ending 2020-12-31 was $0.00.
- Arbutus Biopharma Corp goodwill, impairment loss for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- Arbutus Biopharma Corp goodwill, impairment loss for the quarter ending 2019-12-31 was $0.00.
- Arbutus Biopharma Corp goodwill, impairment loss for the quarter ending 2019-09-30 was $22.47M.
- Arbutus Biopharma Corp goodwill, impairment loss for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- Arbutus Biopharma Corp goodwill, impairment loss for fiscal 2019 was $22.47M.
- Arbutus Biopharma Corp goodwill, impairment loss for fiscal 2018 was $0.00.
- Arbutus Biopharma Corp goodwill, impairment loss for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
| Period end | Goodwill, Impairment Loss 3 month | Goodwill, Impairment Loss 6 month | Goodwill, Impairment Loss 6 month as first filed | Goodwill, Impairment Loss 9 month | Goodwill, Impairment Loss 9 month as first filed | Goodwill, Impairment Loss 12 month |
|---|---|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $0.00 derived: sum of 2 quarters · filed 2021-03-04 | $0.00 10-K · filed 2021-03-04 | |||
| 2020-09-30 | $0.00 10-Q · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | ||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $22.47M derived: sum of 2 quarters · filed 2021-03-04 | $22.47M 10-K · filed 2021-03-04 | |||
| 2019-09-30 | $22.47M 10-Q · filed 2020-11-05 | $22.47M 10-Q · filed 2020-11-05 | ||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $0.00 derived: sum of 2 quarters · filed 2020-03-05 | $0.00 derived: sum of 3 quarters · filed 2020-03-05 | $0.00 10-K · filed 2020-03-05 | ||
| 2018-09-30 | $0.00 10-Q · filed 2019-11-06 | $0.00 derived: sum of 2 quarters · filed 2019-11-06 | $0.00 10-Q · filed 2019-11-06 | $0.00 derived: sum of 4 quarters · filed 2019-11-06 | ||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $0.00 10-Q · filed 2018-08-03 | $0.00 derived: sum of 3 quarters · filed 2019-03-07 | $0.00 derived: sum of 4 quarters · filed 2019-03-07 | ||
| 2018-03-31 | $0.00 10-Q · filed 2018-05-04 | $0.00 derived: sum of 2 quarters · filed 2019-03-07 | $0.00 derived: sum of 3 quarters · filed 2019-03-07 | $0.00 derived: sum of 4 quarters · filed 2019-03-07 | ||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $0.00 derived: sum of 2 quarters · filed 2019-03-07 | $0.00 derived: sum of 3 quarters · filed 2019-03-07 | $0.00 10-K · filed 2019-03-07 | ||
| 2017-09-30 | $0.00 10-Q · filed 2018-11-07 | $0.00 derived: sum of 2 quarters · filed 2018-11-07 | $0.00 10-Q · filed 2018-11-07 | -$18.17M derived: sum of 4 quarters · filed 2018-11-07 | ||
| 2017-06-30 | $0.00 10-Q · filed 2018-08-03 | $0.00 10-Q · filed 2017-08-03 | -$18.17M derived: sum of 3 quarters · filed 2018-08-03 | -$18.17M derived: sum of 4 quarters · filed 2018-08-03 | ||
| 2017-03-31 | $0.00 10-Q · filed 2018-05-04 | -$18.17M derived: sum of 2 quarters · filed 2018-05-04 | -$18.17M derived: sum of 3 quarters · filed 2018-05-04 | $138.15M derived: sum of 4 quarters · filed 2018-05-04 | ||
| 2016-12-31 | -$18.17M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | -$18.17M derived: sum of 2 quarters · filed 2018-03-16 | $138.15M derived: sum of 3 quarters · filed 2018-03-16 | $138.15M 10-K · filed 2018-03-16 | ||
| 2016-09-30 | $0.00 10-Q · filed 2017-11-02 | $156.32M derived: sum of 2 quarters · filed 2017-11-02 | $156.32M 10-Q · filed 2017-11-02 | $0.00 10-Q · filed 2016-11-03 | ||
| 2016-06-30 | $156.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $156.32M 10-Q · filed 2017-08-03 | $0.00 10-Q · filed 2016-08-04 | |||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-04 | |||||
| 2015-12-31 | $0.00 10-K · filed 2018-03-16 | |||||
| 2014-12-31 | $0.00 10-K · filed 2017-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |